Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

3.950 -0.750 (-15.96%)

Streaming Delayed Price Updated: 10:31 AM EST, Jan 16, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,224,421
Open	3.935
Bid (Size)	3.950 (300)
Ask (Size)	3.960 (22,100)
Prev. Close	4.700
Today's Range	3.680 - 4.120
52wk Range	2.705 - 5.100
Shares Outstanding	99,161,234
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

Today 9:40 EST

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...

Via Finterra

Get insights into the top gainers and losers of Friday's pre-market session. ↗

Today 8:30 EST

Via Chartmill

Performance

YTD	-17.2%	-17.2%
1 Month	-13.9%	-13.9%
3 Month	-12.4%	-12.4%
6 Month	+25.8%	+25.8%
1 Year	+20.4%	+20.4%

More News

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Via Finterra

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

Via MarketMinute

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Via PredictStreet

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗

October 21, 2025

Via Chartmill

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

October 07, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus (ABUS) Q2 Revenue Surges 529% ↗

August 06, 2025

Via The Motley Fool

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 06, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

June 25, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 07, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

April 23, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

March 27, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

March 03, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

February 25, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Provides 2025 Corporate and Financial Update

January 13, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

December 03, 2024

From Whitefort Capital Management, LP

Via Business Wire

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

November 26, 2024

From Arbutus Biopharma Corporation

Via GlobeNewswire

Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 20, 2024

Via Benzinga

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

November 15, 2024

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

November 15, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

Arbutus to Present at Jefferies London Healthcare Conference

November 14, 2024

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 06, 2024

From Arbutus Biopharma Corporation

Via GlobeNewswire

Frequently Asked Questions

Is Arbutus Biopharma Corporation - Common Stock publicly traded?

Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.

What exchange does Arbutus Biopharma Corporation - Common Stock trade on?

Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?

The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market

What is the current price of Arbutus Biopharma Corporation - Common Stock?

The current price of Arbutus Biopharma Corporation - Common Stock is 3.950

When was Arbutus Biopharma Corporation - Common Stock last traded?

The last trade of Arbutus Biopharma Corporation - Common Stock was at 01/16/26 10:31 AM ET

What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?

The market capitalization of Arbutus Biopharma Corporation - Common Stock is 391.69M

How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?

Arbutus Biopharma Corporation - Common Stock has 392M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.